Healthcare Pharma Services

List of Contract Research Stocks

Contract Research is part of the Pharma Services group in the Healthcare sector. Its 42 US-listed companies are worth $478.49 billion between them. The median is $568.80 million. 11 have Contract Research as their primary business, and 31 more run a substantial one alongside another industry.

Companies 42
Combined market cap $478.49 Bn
Median market cap $568.80 Mn
Average move -3.76%
Industry
List of Contract Research Stocks Healthcare 42 companies last close
Symbol Company Mkt Cap Price Chg % 1Y Revenue (TTM) Revenue (Qtr) Net Income (TTM) P/E Net Margin (TTM) Div. Yield Why this company is listed here
TMO 2nd Thermo Fisher Scientific $250.84Bn 676.99 -4.11% +19.26% 47.35Bn 12.14Bn 7.09Bn 36.45 14.94% 0.00%
IQV Iqvia Holdings $43.65Bn 264.86 +0.43% +26.05% 17.31Bn 4.43Bn 1.40Bn 32.07 8.05% 0.00%
LH 2nd Labcorp Holdings $29.49Bn 363.13 -1.26% +44.85% 14.59Bn 3.81Bn 1.00Bn 29.85 6.88% 0.00%
GH 2nd Guardant Health $20.67Bn 153.43 -8.99% +61.42% 1.28Bn 360.98Mn -485.07Mn -41.46 -37.93% 0.00%
MEDP Medpace Holdings $17.76Bn 634.98 -3.32% +6.04% 2.84Bn 716.00Mn 517.83Mn 35.27 18.24% 0.00%
LDOS 2nd Leidos Holdings $16.57Bn 135.86 +0.10% -30.35% 17.80Bn 4.63Bn 1.44Bn 11.61 7.97% 0.01%
ICLR Icon $15.44Bn 201.65 -0.72% +23.18% 8.23Bn 2.02Bn 448.66Mn 35.79 5.45% 0.00%
CRL Charles River Laboratories International $14.99Bn 313.13 -3.83% +86.72% 3.98Bn 982.73Mn 39.65Mn 402.13 1.01% 0.00%
TEM 2nd Tempus AI $12.46Bn 70.28 -7.05% -14.56% 1.51Bn 411.54Mn -189.29Mn -72.91 -12.54% 0.00%
DVA 2nd Davita $12.34Bn 194.64 +1.08% +60.65% 14.17Bn 3.58Bn 1.22Bn 13.27 6.49% 0.00%
RDY 2nd Dr Reddys Laboratories $12.12Bn 14.52 -1.69% +8.36% 3.56Bn 907.15Mn 299.19Mn 34.11 10.21% 0.00%
TWST 2nd Twist Bioscience $7.56Bn 120.61 -15.41% +282.65% 431.80Mn 118.38Mn -136.80Mn -55.20 -31.68% 0.00%
CAI 2nd Caris Life Sciences $7.46Bn 26.03 -21.64% -10.89% 1.05Bn 275.36Mn 96.06Mn 74.90 9.16% 0.00%
ADPT 2nd Adaptive Biotechnologies $4.34Bn 26.80 +0.34% +52.36% 298.01Mn 83.90Mn -70.73Mn -63.68 -23.66% 0.00%
ABCL 2nd AbCellera Biologics $3.40Bn 11.11 -9.53% +136.89% 66.17Mn 4.05Mn -164.66Mn -22.11 -248.83% 0.00%
NEO 2nd Neogenomics $2.13Bn 16.49 -3.85% +58.10% 787.75Mn 209.25Mn -32.30Mn -67.07 -4.10% 0.00%
FTRE Fortrea Holdings $1.97Bn 20.46 -1.78% +71.21% 2.67Bn 691.50Mn -68.70Mn -30.57 -2.58% 0.00%
OABI 2nd OmniAb $704.48Mn 4.83 -6.76% +240.14% 40.21Mn 3.99Mn -43.47Mn -15.00 -108.11% 0.00%
STLN 2nd Starling Oncology $670.13Mn 6.67 -3.89% +63.08% 587.24Mn 161.28Mn -36.29Mn -11.93 -5.20% 0.00%
DNA Ginkgo Bioworks Holdings $633.93Mn 9.95 -14.59% -14.15% 111.86Mn 20.16Mn -290.80Mn -2.41 -259.96% 0.00%
EVO Evotec SE $629.34Mn 1.77 +12.74% -47.16% — — — — — 0.00%
YDES 2nd YD Bio $508.27Mn 7.18 +3.31% -31.88% — — — — — 0.00%
WDH 2nd Waterdrop $360.88Mn 1.00 +0.00% -39.76% 732.27Mn 213.44Mn 78.34Mn 6.31 7.82% 0.00%
CLPT 2nd ClearPoint Neuro $277.91Mn 8.67 -14.67% -48.94% 45.49Mn 12.08Mn -36.14Mn -7.37 -79.43% 0.00%
BDSX 2nd Biodesix $220.00Mn 19.84 -7.68% +130.70% 105.21Mn 24.04Mn -27.08Mn -3.35 -25.74% 0.00%
IMRX 2nd Immuneering $218.25Mn 3.37 -10.37% -47.43% — — -66.50Mn -3.58 — 0.00%
XGN 2nd Exagen $184.35Mn 7.62 -10.46% -26.23% 71.12Mn 19.94Mn -18.92Mn -7.37 -26.61% 0.00%
KRMD 2nd KORU Medical Systems $139.83Mn 3.03 -7.34% -24.81% 45.11Mn 12.05Mn -1.82Mn -77.89 -4.03% 0.00%
BNR 2nd Burning Rock Biotech $139.37Mn 13.25 +3.27% +8.61% 72.00Mn 19.86Mn -11.22Mn -12.20 -13.60% 0.00%
MXCT 2nd Maxcyte $139.04Mn 1.31 -5.76% -21.56% 31.05Mn 7.27Mn -35.64Mn -3.73 -114.77% 0.00%
AGPU 2nd Axe Compute $119.10Mn 6.05 -18.68% -5.47% — — -253.50Mn -0.52 — 0.00%
IMDX 2nd Insight Molecular Diagnostics $80.25Mn 2.46 -7.17% -63.06% 1.67Mn 239.00K -49.36Mn -1.85 -2,955.63% 0.00%
NTRB 2nd NutriBand $67.71Mn 5.57 -8.39% -6.39% 1.62Mn 437.51K -6.96Mn -9.63 -430.43% 0.00%
CSBR Champions Oncology $66.25Mn 4.76 -2.06% -30.00% 60.66Mn 15.23Mn -1.16Mn -60.43 -1.82% 0.00%
XBIT 2nd XBiotech $57.01Mn 1.87 -4.59% -11.79% — — -45.13Mn -1.27 — 0.00%
HYFT MindWalk Holdings $46.71Mn 1.00 -3.85% -44.75% 11.72Mn 2.75Mn -12.32Mn -3.97 -105.16% 0.00%
PBSV 2nd Pharma-Bio Serv $11.91Mn 0.52 +0.00% -5.45% 9.48Mn 2.34Mn -79.24K 47.35 2.65% 13.46%
BFRG 2nd BullFrog AI Holdings $9.09Mn 0.49 -7.55% -53.33% 332.06K 215.39K -6.00Mn -1.60 -1,805.87% 0.00%
VSBC 2nd Vitaspring Biomedical $6.21Mn 0.03 +0.00% -97.00% — — -455.64K -13.60 — —
VIVS VivoSim Labs $733.52K 0.14 -6.67% -93.86% 112.00K 18.00K -12.34Mn -0.06 -11,016.07% 0.00%
CPMV 2nd Mosaic ImmunoEngineering $579.37K 0.08 +0.00% -91.01% — — -681.88K -0.85 — 0.00%
CBIH Cannabis Bioscience International Holdings $0.00 0.00 — — — — — — — —

Showing 30 of 42 Contract Research companies

Create a free account to see the remaining 12, sort the full list on any column, and choose your own metrics.

Free, no card. Already have an account? .

  • 2nd a substantial business here, but not the company’s largest
  • Prices and market caps as of the last close
  • Click any column heading to sort

About this list

How many Contract Research stocks are there?

This list holds 42 US-listed companies, of which 11 have Contract Research as their primary business. The rest operate a substantial Contract Research business alongside something else, which is why they appear here as well as on their own primary list.

How is this list put together?

Every US-listed company is classified under BQ-MICS, our own multi-industry classification system. Unlike a single-label scheme it assigns each company a primary industry AND any secondary industries it genuinely operates in, and it records the reasoning behind every assignment — which you can read on each row of the table above.

Why do some companies appear on more than one list?

Because they genuinely operate more than one business. A retailer running a large cloud division belongs on both lists, and a classification that forces it onto one is hiding half the company. Every appearance beyond the primary one is labelled as secondary, and the toggle above the table hides them if you only want pure plays.

How often is this list updated?

Prices, market caps and performance figures refresh with each session's close. The classification itself is reviewed whenever a company's filings change what it does — a new segment, a disposal or an acquisition — rather than on a fixed calendar.

Can I screen these companies on other metrics?

Yes. Use Edit Columns above the table to add any of 1,000+ financial metrics and ratios to this list, or open the full stock screener to filter the whole market on them.